文献速递主动脉疾病

钝性胸主动脉损伤TEVAR术后长期生存结果

Long-Term Survival following TEVAR for Blunt Thoracic Aortic Injury.
PubMed 文献 · Ann Vasc Surg · 2026-03-25

该单中心回顾性研究纳入2002至2025年加拿大麦吉尔大学46例接受TEVAR治疗的钝性胸主动脉损伤患者,评估长期结局。中位随访116个月,主动脉相关死亡率为0%,总生存率1年100%、3年97.6%、10年90.8%,TEVAR安全耐久。

要点

  • TEVAR治疗BTAI长期主动脉相关死亡率为0%,10年总生存率90.8%。
  • 多数损伤为SVS III级(78.3%),位于2区和3区(65.2%和26.1%)。
  • 左锁骨下动脉覆盖率60.9%,无长期后遗症。

核心结论

  • TEVAR是BTAI安全且持久的治疗方法,长期结局优异。

研究设计与样本

  • 单中心回顾性研究,纳入2002至2025年麦吉尔大学46例接受TEVAR治疗的BTAI患者。
  • 随访包括系列CT影像和临床评估,分析生存率和再干预率。

主要发现

  • 中位年龄43.5岁(范围16-89岁),男性占73.9%。
  • 中位修复时间11小时,82.6%在24小时内接受TEVAR。
  • 围手术期并发症6.5%,均与股动脉入路相关,无卒中、截瘫或30天死亡。
  • 中位随访116个月(9.6年),主动脉相关死亡率0%,非主动脉相关死亡率10.9%。
  • Kaplan-Meier分析显示总生存率1年100%、3年97.6%、10年90.8%。

临床怎么用

  • TEVAR可作为BTAI的首选治疗,需及时干预。
  • 根据主动脉解剖和器械选择进行个体化规划以优化生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Blunt thoracic aortic injury (BTAI) is a leading cause of death in blunt chest trauma. Thoracic endovascular aortic repair (TEVAR) has emerged as the preferred treatment, offering reduced morbidity and improved survival compared with open repair. This study evaluates long-term outcomes of TEVAR for BTAI at a single Canadian center. METHODS: We retrospectively reviewed 46 patients with BTAI treated with TEVAR at McGill University from 2002 to 2025. Data collected included demographics, associated injuries, Society for Vascular Surgery (SVS) grade, aortic zone, procedural details, and outcomes. Follow-up consisted of serial computed tomography imaging and clinical assessment. Survival and reintervention rates were analyzed. RESULTS: Median age was 43.5 years (range 16-89 years), with 73.9% male. Most injuries were SVS grade III (78.3%) and located in zones 2 and 3 (65.2% and 26.1%). Median time to repair was 11 hours; 82.6% underwent TEVAR within 24 hours. Males had larger proximal aortic diameters and received larger stent grafts, while oversizing percentages were similar between sexes. Device selection evolved over time, reflecting greater availability of low-profile grafts. Left subclavian artery coverage was performed in 60.9% of patients without long-term sequelae. Immediate complications occurred in 6.5%, all related to femoral access, with no strokes, paraplegia, or 30-day mortality. Over a median follow-up of 116 months (9.6 years), long-term aorta-related mortality was 0%, while non aorta-related mortality was 10.9%. Kaplan-Meier analysis demonstrated overall survival of 100%, 97.6%, and 90.8% at 1, 3, and 10 years, respectively. CONCLUSION: TEVAR is a safe and durable treatment for BTAI, with excellent long-term outcomes. Timely intervention and individualized planning based on aortic anatomy and device selection are critical to optimize survival.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gonzalez-Urquijo M, Laor B, Lioupis C, et al. Long-Term Survival following TEVAR for Blunt Thoracic Aortic Injury. Ann Vasc Surg. 2026. PMID: 41895585. doi:10.1016/j.avsg.2026.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。